17:38 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample and mouse studies suggest inhibiting NEK2 could help treat Velcade bortezomib-resistant MM. In MM patients, high levels of NEK2 in bone marrow plasma cells were associated with poor overall and...
01:10 , Dec 7, 2016 |  BC Extra  |  Clinical News

GNS identifies disease drivers from CoMMpass data

GNS Healthcare Inc. (Cambridge, Mass.) said it has identified four genes as "top drivers" of high-risk multiple myeloma. Using its machine learning technology, the company is collaborating with the Multiple Myeloma Research Foundation (MMRF) to...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer NDC80 homolog kinetochore complex component (NDC80); NIMA-related kinase 2 (NEK2) SAR studies suggest compounds that block...